摘要
腋窝前哨淋巴结活检术(SLNB)已成为临床腋窝淋巴结阴性的早期乳腺癌患者首选的腋窝术式。示踪剂的合理选择是乳腺癌SLNB的重要技术环节之一。理想的示踪剂应具有合适的大小,靶向性强,优秀的可视性,相对低廉的价格以及具有充足的循证医学证据支持等特性。本文从示踪剂的靶向性、可视性、经济适用性以及循证医学证据等4个方面综述了国内外乳腺癌SLNB常用的示踪剂(蓝染料、以胶体或克隆抗体为载体的核素示踪剂和纳米碳)以及新型示踪剂(吲哚菁绿、超顺磁性氧化铁、超声造影剂和示踪用盐酸米托蒽醌注射液)的优缺点、应用现状和研究进展,以期为临床一线工作者对乳腺癌SLNB示踪剂的选择提供一定的参考。
Sentinel lymph node biopsy( SLNB) has become the standard procedure for the axillary stage in early breast cancer patients.Reasonable selection of tracer is one of the important technical aspects of SLNB in breast cancer. Ideal tracers should have appropriate size,strong targeting,excellent visibility,relatively low prices and supported by evidence-based medical evidence. In this paper, the advantages,disadvantages,application status and research progress of commonly used tracers( blue dye,colloidal or clonal antibody-based radionuclide tracers and nano-carbon) and new tracers( indocyanine green,superparamagnetic iron oxide,ultrasound contrast agent and mitoxantrone hydrochloride injection for tracing) for breast cancer SLNB in China and abroad were reviewed from the four aspects of targeting, visibility,economic applicability and evidence-based medicine evidence. in order to provide a reference for the selection of breast cancer SLNB tracers for clinical front-line workers.
作者
孙晓
陈玉光
邱鹏飞
王永胜
SUN Xiao;CHEN Yu-guang;QIU Peng-fei;WANG Yong-sheng(The Department of Breast Surgery,Shandong Cancer Hospital and Institute,Shandong First Medical University,Jinan 250117,Shandong Province,China)
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2022年第4期347-351,共5页
The Chinese Journal of Clinical Pharmacology
基金
山东省医药卫生科技发展计划基金资助项目(2019WS201)。
